SIR-Spheres® Y-90 resin microspheres + mFOLFOX6 +/- biological*
- did not add a benefit in Overall Survival1, but:
- significantly increased Response Rate and median Progression Free Survival in the liver,1,2
- resulted in a clinically relevant improvement in Overall Survival in patients with liver metastases from Right Sided Primary (RSP) tumours,
- showed a Safety and Tolerability profile as expected and manageable.
*Bevacizumab in SIRFLOX and FOXFIRE Global, bevacizumab or cetuximab in FOXFIRE and biologicals allowed at investigator’s discretion, per institutional practice.
1. Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
2. Van Hazel G et al. J Clin Oncol 2016; 34:1723–1731.